Cohance Lifesciences Limited, a technology-driven, integrated CDMO platform, has appointed Umang Vohra as Executive Chairman, effective May 1, 2026, and Group CEO, effective May 20, 2026.

Vohra succeeds Vivek Sharma, who is stepping down as Executive Chairman for personal reasons. Sharma will continue as an Advisor for the next nine months to support a smooth transition.

Vohra brings more than three decades of leadership experience in the pharmaceutical industry, having led large, complex global businesses through periods of transformation with a strong focus on customers, quality, and operational excellence. Most recently, as CEO and Managing Director of Cipla Limited, he steered the company’s transformation into a diversified global pharmaceutical enterprise. 

Umang Vohra said, “I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance’s technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation. I am looking forward to this entrepreneurial stint and will work closely with the current management leaders to create value for customers, employees and shareholders alike.”

Vivek Sharma said, “Over the past few years, we have built a strong foundation for Cohance — integrating businesses, strengthening the leadership team, and establishing the platform’s identity as a science-led CDMO.”

Pankaj Patwari, Managing Director at Advent International, said, “I am excited to welcome Umang to the Cohance family. The platform will greatly benefit from a leader like Umang, who brings an owner-manager mindset and can build on the business’s scientific foundation, drive commercial scale, deepen customer partnerships, and develop a leading operating culture.”